Cosmetic and aesthetic laser maker Candela
After promising "white hot" sales of its premier GentleYAG laser last year, the company disappointed investors with progressively declining earnings. Then, last quarter it decided that lasers were no longer the technology to carry the company into the future, but rather intense pulsed light technology -- an area where competitors like Palomar Medical Technologies
Candela's revenues and earnings should be growing. Laser and light-based cosmetic and aesthetic treatments are estimated to be a $3.3 billion market, up from $2.2 billion in 2002, with more than 4.4 million procedures performed this year. Moreover, medical practitioners no longer need to be specialists or plastic surgeons. Laser and pulsed light technology allows just about any doctor to perform the procedures. Candela has an installed base of over 8,000 lasers in 64 countries used by a broad mix of OB/GYNs, family practitioners, and dermatologists, as well as general, vascular, and plastic surgeons.
Cosmetic lasers differ from the types of lasers used by Motley Fool Hidden Gems pick Rofin-Sinar
Palomar Medical reported record earnings yesterday, with revenues up 57% and earnings exploding over 200% year over year. It even has an agreement with Gillette
Candela's lasers have been seen as leading edge, and when a new technology comes along that can help boost the top and bottom lines -- as pulsed light systems have the potential to do -- well, it does need to move in. Still, last year at this time Candela promised great things and wasn't able to deliver. Last quarter it pinned its fortunes on the new technology. But the spotty record of this one-time fast track rocket leaves me feeling leery about its ultimate potential.
Beam in on the laser industry with these related bits of Foolishness:
- Candela's Lasers Offer Dim View
- Laser Beamer Lookin' Good
- Profit From Management Integrity
- Lasers Lose Focus
Tom Gardner is trouncing the market better than 6 to 1 with his selections at Hidden Gems. Take a 30-day free trial to see his latest recommendations.
Fool contributor Rich Duprey gets an intense pulse at the sight of a Krispy Kreme doughnut. He owns shares in Candela but does not own any of the other stocks mentioned in the article.